GENE ONLINE|News &
Opinion
Blog

2021-08-20| Asia-Pacific

GenScript’s Biotech Unit, ProBio Bags $150 Million in Series A from Hillhouse Capital

by Joy Lin
Share To

ProBio Cayman, a subsidiary of Hong Kong-listed GenScript Biotech Corporation, has struck a $150 million Series A investment deal with private equity firm Hillhouse Capital Group, according to a filing made to the Hong Kong Stock Exchange by parent company GenScript on Thursday.

The deal comes in two parts. As per the agreement, ProBio will first issue 300 million Series A preferred shares (with a combined value of around $150 million) to Hillhouse. The investor stands to gain 17.05% ownership of ProBio following the deal.

Hillhouse will also possess the right to purchase another 189.4 million shares (combined value: around $125 million) from ProBio. This could potentially boost its stake in ProBio to 20.68%.

 

Confident Investor Backing

 

This is all good news for GenScript’s ProBio. The contract development and manufacturing organization (CDMO) was originally established as the parent’s Biologics Development Business Unit in January 2019. ProBio’s platform services cover therapeutic antibodies and gene & cell therapy. The company promises to help clients accelerate drug development from discovery to commercialization, a straight flush from target to market.

Using the influx of cash, ProBio will expand its Good Manufacturing Practice (GMP) manufacturing capacity and enhance its R&D platform in order to develop its existing business.

This is not the first time Hillhouse has signaled interest in GenScript’s businesses. Earlier in mid-May, Genscript raised over $1 billion from Hillhouse Capital in several different investments. This included a $500 million commitment to GeneScript’s Legend Biotech, a subsidiary advancing CAR-T cell therapy.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Experts Weigh In on AI’s Role, Challenges, and Future in Drug Discovery at the 2025 Taiwan Biotech Forum
2025-06-16
Amaran Biotech Crowned “Best CDMO in Automated Aseptic Filling” at Taiwan Biopharma Excellence Awards 2025!
2025-03-26
From Labs to Breakthroughs: HanchorBio Aims High in the Immuno-Oncology Market with HCB101
2025-02-17
LATEST
University of Pittsburgh Study Finds Flu Vaccines Prevent Up to 41.5 Percent of Infections in Simulated Communities
2025-07-19
Pharmacist-Led Initiatives Boost Pneumococcal Vaccine Uptake Among Older Adults Through Education and Direct Immunization Services
2025-07-19
Study Finds Agricultural Dust Exposure Alters Gut Microbiota and Weakens Intestinal Barrier in Mice
2025-07-19
Biotech Leaders Urge FDA to Reject Conservative Report Criticizing Mifepristone Safety Profile
2025-07-19
Physician Calls for Better Diagnosis of Cannabinoid Hyperemesis Syndrome Amid Discussions on Drug Pricing and Accessibility
2025-07-19
Maternal Vaccination Linked to Reduced RSV Hospitalizations in Newborns
2025-07-18
FDA Advisory Committee Votes Against Approval of GSK’s Blenrep Ahead of PDUFA Date
2025-07-18
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top